Top stories in cardiology: NSAID safety profiles, coffee consumption and more

Among the top stories in cardiology is a post-hoc analysis showing that celecoxib had a better CV safety profile vs. ibuprofen and naproxen among patients not taking aspirin. Another study suggests that regularly drinking coffee — up to three cups per day — is safe and could reduce the frequency of arrhythmias.

Other top headlines include more intensive LDL lowering, the use of ambulatory BP measurements to predict mortality, and non-CV comorbidities in patients with HF.

CV effects of NSAIDs similar when combined with aspirin

In a new post hoc analysis from the PRECISION trial, celecoxib had a better CV safety profile vs. ibuprofen and naproxen among patients not taking aspirin, but significant differences in CV events were not seen in patients taking aspirin. Read More.

Review: Coffee, tea consumption may mitigate arrhythmia risk

Drinking up to three cups of coffee per day is safe and might even reduce the frequency of arrhythmias, according to a review recently published in JACC: Clinical Electrophysiology. Read More.

More intensive LDL lowering decreases risk for CV, total mortality

Patients with higher baseline LDL levels who underwent more intensive LDL lowering had a greater risk reduction of total and CV mortality compared with those with less intensive treatment, according to a meta-analysis published in JAMA. Read More.

Ambulatory BP measurements strong predictors of mortality

Ambulatory BP measurements were better predictors of CV and all-cause mortality compared with clinic BP measurements, according to a study published in The New England Journal of Medicine. Read More.

Non-CV comorbidities often ignored when treating HF

Pathways between CV and non-CV comorbidities in patients with HF were not affected by treatments for HF, according to a study published in PLOS Medicine. Read More.